BESPOKE: ctDNA Clearance During and After ACT

Opinion
Video

Panelists discuss how circulating tumor DNA (ctDNA) clearance rates during and after adjuvant chemotherapy (ACT) in the BESPOKE trial provide critical insights into treatment efficacy and may serve as an early predictor of long-term patient outcomes.

Recent Videos
2 experts in this video
2 experts in this video
Related Content